In a study of patients with upper tract urothelial carcinoma, Asians were 27% more likely than whites to die from the disease.
An FDA pooled analysis suggests that certain AEs were associated with response and overall survival in PD-1/PD-L1-treated urothelial cancer.
The investigators said the data justify and support the submission of enfortumab vedotin for consideration under FDA’s accelerated approval pathway.
Longer follow-up of patients in the KEYNOTE-052 trial confirms the anti-tumor effect of first-line pembrolizumab in patients with cisplatin-ineligible advanced urothelial carcinoma.
The median duration of complete response to atezolizumab in patients with locally advanced or metastatic urothelial carcinoma is more than 2 years, new data suggest.
In a phase 2 study, patients with metastatic urothelial carcinoma who had stable disease on first-line platinum-based chemotherapy experienced a delay in disease progression when switched to pembolizumab.
Failing to use metformin for diabetes treatment was among the more surprising risk factors for bladder cancer recurrence following surgery for upper tract urothelial carcinoma.
In a study, median survival time was significantly shorter among patients managed nonsurgically rather than surgically for localized upper tract urothelial carcinoma.
In a phase 2 trial, more than half of patients who received neoadjuvant chemotherapy for high-risk upper tract urothelial carcinoma had a pathologic response that was associated with improved survival.
In a small study of patients who underwent radical surgery for upper tract urothelial carcinoma, investigators found no evidence of tract seeding.